Cocrystal Pharma Inc. has received approval from the Institutional Review Board (IRB) at Emory University School of Medicine to initiate a Phase 1b human challenge study with its oral antiviral drug candidate, CDI-988, for the prevention and treatment of norovirus infections. This follows earlier clearance from the U.S. Food and Drug Administration (FDA) of Cocrystal’s investigational New Drug $(IND)$ application. Subject enrollment for the study is expected to begin in the first quarter of 2026. No grant or funding involving multiple organizations is mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604116) on December 18, 2025, and is solely responsible for the information contained therein.